BBA
IOVA icon

Baker Bros. Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Baker Bros. Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,066,285
Closed -$5.42M – 136
2016
Q1 		$5.42M Sell
1,066,285
-751,144
-41% -$4.11M 0.06% 72
2015
Q4 		$14M Hold
1,817,429
– – 0.12% 55
2015
Q3 		$10.5M Hold
1,817,429
– – 0.1% 61
2015
Q2 		$16.7M Buy
1,817,429
+492,429
+37% +$5.5M 0.15% 53
2015
Q1 		$16M Buy
+1,325,000
New +$14.9M 0.13% 50

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baker Bros. Advisors's IOVA Position: Q2 2016 in Review

Baker Bros. Advisors sold out of Iovance Biotherapeutics (IOVA) in Q2 2016, closing a stake of 1,066,285 shares — an estimated $5.42M sold.

Baker Bros. Advisors first reported a position in IOVA in Q1 2015 and held it in 5 quarters. The position peaked at $16.7M in Q2 2015. 82 funds tracked by Wall St. Rank hold IOVA as of Q2 2016.

  • Baker Bros. Advisors reported no remaining Iovance Biotherapeutics position as of Q2 2016 after selling out during the quarter.
  • Baker Bros. Advisors sold 1,066,285 Iovance Biotherapeutics shares in Q2 2016, an estimated $5.42M.
  • Baker Bros. Advisors first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 5 quarters.
  • Baker Bros. Advisors's Iovance Biotherapeutics position peaked at $16.7M in Q2 2015.
  • 82 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2016.

Based on Baker Bros. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.